ARTICLE DOWNLOAD

Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy

10$
ARTICLE DOWNLOAD

Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy

10$

O. C. Smibert, M. A. Slavin, B. Teh, A. G. Heriot, J. Penno, H. Ismail, K. A. Thursky & L. J. Worth 

Abstract

Background

CRS-HIPEC is associated with improved cancer survival but an increased risk of infection.

Methods

Consecutive patients undergoing CRS-HIPEC between January 2016 and May 2018 were retrospectively reviewed. Malignancy type, comorbidities, perioperative risk factors and infectious complications were captured, using standardised definitions. Association between risk factors and infection outcomes was evaluated by logistic regression modelling.

Results

One-hundred patients underwent CRS-HIPEC, predominantly for colorectal cancer and pseudomyxoma peritonei. Overall, 43 (43.0%) experienced an infectious complication, including infections at surgical site (27), respiratory tract (9), urinary tract (11), Clostridium difficile (2) and post-operative sepsis (15). In most, infection onset was within 7 days post-operatively. Median length of hospitalisation was 19 days for patients with infection, compared to 8 days for those without (p = 0.000). There were no deaths at 60 days. Of variables potentially associated with surgical site infection, small bowel resection (OR 4.01, 95% confidence interval [CI] 1.53–10.83; p = 0.005) and number of resected viscera (OR 1.41, 95% CI 1.00–1.98; p = 0.048) were significantly associated with infection.

Conclusions

We demonstrate a significant burden of early infective complications in patients undergoing CRS-HIPEC. Higher-risk subgroups, including those with small bowel resection and increased number of resected viscera, may benefit from enhanced monitoring.

Only units of this product remain
Year 2020
Language English
Format PDF
DOI 10.1007/s00520-019-05093-5